Contact
searchSearch
HMP Global
Login

Cholangiocarcinoma Resource Center

Aiwu Ruth He, MD
PATHWAY DISRUPTORS
TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer
11/17/2023
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD,...
11/17/2023
Journal of Clinical Pathways
News
Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments
11/17/2023
Emry Lloyd
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling...
11/17/2023
Journal of Clinical Pathways
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
11/17/2023
Allison Casey
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the...
11/17/2023
Journal of Clinical Pathways
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
11/17/2023
Allison Casey
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific...
11/17/2023
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer
11/17/2023
Brandon Twyford
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration...
11/17/2023
Journal of Clinical Pathways

Aiwu Ruth He, MD
PATHWAY DISRUPTORS
TOPAZ-1 Study Explores Potential Prognostic Factors of Overall Survival for Patients With Advanced Biliary Tract Cancer
11/17/2023
Aiwu Ruth He, MD, PhD
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD, summarizes the phase 3 TOPAZ-1 study and discusses treatment approaches for patients with biliary tract cancer.
Aiwu Ruth He, MD, PhD,...
11/17/2023
Journal of Clinical Pathways
News
Real-World Evidence Study Reveals Improved Survival in Biliary Tract Cancer Through Molecular Targeted Treatments
11/17/2023
Emry Lloyd
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling for targeted treatments has shown a significant improvement in survival outcomes for patients with biliary tract cancer, according to a new study based on real-world evidence.
The use of molecular profiling...
11/17/2023
Journal of Clinical Pathways
NUC-1031 Did Not Prolong Overall Survival for Patients With Advanced Biliary Tract Cancers
11/17/2023
Allison Casey
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the phosphoramidate transformation of gemcitabine, NUC-1031 plus cisplatin did not prolong the overall survival, compared with gemcitabine-cisplatin, among patients with advanced biliary tract cancer.
In a phase 3 study, the...
11/17/2023
Journal of Clinical Pathways
News
Zanidatamab Shows Promise for HER2-Positive, Unresectable Biliary Tract Cancer
11/17/2023
Allison Casey
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific antibody targeting 2 distinct HER2 epitopes, demonstrates meaningful clinical benefit with a manageable safety profile among patients with refractory, HER2-positive unresectable, locally advanced or metastatic...
Zanidatamab, a bispecific...
11/17/2023
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab in Combination with Chemotherapy for Biliary Tract Cancer
11/17/2023
Brandon Twyford
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration (FDA) has granted approval for the use of pembrolizumab in conjunction with gemcitabine and cisplatin for locally advanced unresectable or metastatic biliary tract cancer (BTC). This decision, announced on...
The Food and Drug Administration...
11/17/2023
Journal of Clinical Pathways
Clinical Pathways NEXT, Free Webinar, CPC, Oncology Pathways
Press Release
HMP Global Launches Clinical Pathways NEXT to Address Real-Time Oncology Pathway Decision-Making
02/03/2026
As oncology innovation accelerates and evidence evolves faster than traditional pathway update cycles, stakeholders need clearer insight into how clinical pathways adapt in real time. Clinical Pathways NEXT, a new, free quarterly virtual...
As oncology innovation accelerates and evidence evolves faster than traditional pathway update cycles, stakeholders need clearer insight into how clinical pathways adapt in real time. Clinical Pathways NEXT, a new, free quarterly virtual...
As oncology innovation...
02/03/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Interview
Reflex NGS and PD-L1 Testing Streamlines Biomarker Turnaround and Treatment Planning in Resectable NSCLC
01/27/2026
Tina Edmonston, MD; David D. Shersher, MD
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David...
01/27/2026
Journal of Clinical Pathways
News
Adoptive Cell Therapy Advances Target Ovarian Cancer Solid Tumor Barriers
01/23/2026
Hannah Musick
A comprehensive review highlights emerging adoptive cell therapy strategies aimed at overcoming immune suppression, antigen heterogeneity, and safety challenges in ovarian cancer.
A comprehensive review highlights emerging adoptive cell therapy strategies aimed at overcoming immune suppression, antigen heterogeneity, and safety challenges in ovarian cancer.
A comprehensive review...
01/23/2026
Journal of Clinical Pathways
News
Medicare Advantage Reduces Use of High-Cost Cancer Drugs Compared With Traditional Medicare
01/22/2026
Lisa Kuhns, PhD, MD
Medicare Advantage (MA) enrollees with colorectal cancer (CRC) and advanced non–small cell lung cancer (NSCLC) were less likely than traditional Medicare (TM) beneficiaries to receive cancer-directed drugs and, when treated, were less likely...
Medicare Advantage (MA) enrollees with colorectal cancer (CRC) and advanced non–small cell lung cancer (NSCLC) were less likely than traditional Medicare (TM) beneficiaries to receive cancer-directed drugs and, when treated, were less likely...
Medicare Advantage (MA)...
01/22/2026
Journal of Clinical Pathways
News
Medicare Advantage Linked to Lower Access to High-Quality Cancer Surgery in US
01/19/2026
Grace Taylor, MS, MA
A national Medicare study found that patients enrolled in Medicare Advantage were significantly less likely than those in traditional Medicare to receive major cancer surgery at high-quality hospitals, highlighting potential network-related...
A national Medicare study found that patients enrolled in Medicare Advantage were significantly less likely than those in traditional Medicare to receive major cancer surgery at high-quality hospitals, highlighting potential network-related...
A national Medicare study found...
01/19/2026
Journal of Clinical Pathways
News
McKesson Report Details Key Trends Shaping US Community Oncology Care
01/14/2026
Grace Taylor, MS, MA
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community...
01/14/2026
Journal of Clinical Pathways
News
2025 US Cancer Disparities Report Highlights Education, Rural Gaps
01/12/2026
Hannah Musick
The American Cancer Society’s 2025 report reveals that education level and rural residence drive larger US cancer mortality disparities than race alone, underscoring the central role of socioeconomic and geographic inequities across the...
The American Cancer Society’s 2025 report reveals that education level and rural residence drive larger US cancer mortality disparities than race alone, underscoring the central role of socioeconomic and geographic inequities across the...
The American Cancer Society’s...
01/12/2026
Journal of Clinical Pathways
News
Real-World Data Show Similar Outcomes for First-Line uHCC Immunotherapy Regimens
01/08/2026
Grace Taylor, MS, MA
Real-world data from 6 US cancer centers show no significant survival differences between atezolizumab/bevacizumab and durvalumab/tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC), with liver function...
Real-world data from 6 US cancer centers show no significant survival differences between atezolizumab/bevacizumab and durvalumab/tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC), with liver function...
Real-world data from 6 US cancer...
01/08/2026
Journal of Clinical Pathways
News
CAR T Therapy Access Remains Uneven Despite Specialist Referral
01/07/2026
Grace Taylor, MS, MA
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred...
01/07/2026
Journal of Clinical Pathways
Conference Coverage
Daratumumab Maintenance Deepens MRD Negativity After ASCT in Multiple Myeloma
12/22/2025
Juliet Gallagher
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD)...
12/22/2025
Journal of Clinical Pathways
JCP Nov-Dec Cover

Current Issue

December 2025
Volume 11
Issue 6
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use